Bengaluru-based Biocon’s new plant in the US is aimed at capturing some of the business from the US government under President Donald Trump who is focussed on bringing the cost of medicines down. However, it’s going to cost Biocon some more of its relatively small margin.
3 Min Read
With its new plant operational in New Jersey, US, Bengaluru-based Bioconis hoping to get some of the business from President Donald Trump’s push for cheaper drugs and local manufacturing. It’s likely to cost the company some of its profit margin.
Continue Reading with
Continue Reading with
CNBC-TV18 Access Membership
Priority Access and Networking: CNBC-TV18’s flagship events
Interaction with CNBC-TV18’s journalists
Webinars & LIVE Q&As with India Inc. Leaders
Exclusive CNBC-TV18 studio & newsroom tours
Premium business insights, expert opinions & analysis
Curated lifestyle privileges & offers
